Clinical Advances in Heart Failure, Cardiogenic Shock and Pulmonary Hypertension Symposium is organized by  and will be held from Apr 25 – 26, 2025 at San Diego Marriott La Jolla, La Jolla, California, United States of America.
Description:
Significant advances in the diagnosis and management of heart failure and pulmonary hypertension continue to emerge, compelling the practice of to constantly evolve. These advances must be consistently implemented into clinical practice to guarantee the best care for patients affected by these conditions. The Clinical Advances in Heart Failure, Cardiogenic Shock and Pulmonary Hypertension Symposium is designed to assist clinicians in correctly diagnosing, treating, and managing patients with heart failure and related conditions. In addition, the symposium will outline optimal strategies for managing cardiogenic shock as well as new and emerging techniques for diagnosing and treating various cardiomyopathies. The symposium is dedicated to providing insight and practical tips with regard to integrating scientific evidence into clinical practice. The goal of the conference is for participants to return to their facilities equipped with the latest evidence base and strategies to improve patient outcomes.
Educational Objectives:
After attending this live activity, participants should be able to:
- Incorporate current and emerging clinical evidence in the assessment, treatment, and management of patients with challenging cardiovascular disease.
- Identify guideline-recommended treatment algorithms for heart failure.
- Compare pharmacological and device therapies for cardiogenic shock.
- Identify racial and gender disparities in cardiac device selection.
- Evaluate current and emerging treatment options for cardiac amyloidosis.
- Describe clinical factors and necessary tests to establish a diagnosis of pulmonary hypertension (PH).
- Assess treatment strategies for patients with PH.
- Employ new interdisciplinary care team strategies to enhance the prevention, diagnosis, and management of various types of heart disease.
2025 Clinical Advances in Heart Failure, Arrhythmias & Cardiogenic Shock Symposium – Topics & Runtime
| No. | Topic | Runtime |
|---|---|---|
| 1 | How to PERT | 15:50 |
| 2 | Hemodynamically Unstable Pulmonary Embolism | 15:09 |
| 3 | Arrhythmias & Palpitations in Women | 18:04 |
| 4 | Racial & Gender Disparities in Cardiac Device Selection | 15:07 |
| 5 | The Language of Shock: SCAI Staging System | 14:32 |
| 6 | Which Device for Which Patient: When to Escalate | 12:43 |
| 7 | About Cardiorenal Syndrome | 15:39 |
| 8 | Cardio-Oncology: Immune Checkpoint Inhibitor–Associated Myocarditis | 18:41 |
| 9 | Basic Principles in Management of Adults with Congenital Heart Disease | 16:23 |
| 10 | Treatment of Cardiac Sarcoid | 15:39 |
| 11 | Remote Titration in Heart Failure to Optimize GDMT: Novel or Needed? | 10:43 |
| 12 | Population Health and Heart Failure: Addressing the Implementation Gap | 11:45 |
| 13 | Exercise Hemodynamics | 17:34 |
| 14 | Device-Based Therapies for HFrEF: Beyond CRT-D? | 15:31 |
| 15 | Advanced Imaging in the Diagnosis of Cardiomyopathies | 14:42 |
| 16 | What’s New in HFpEF Trials | 15:27 |
| 17 | HFpEF and Pulmonary Venous Hypertension | 13:40 |
| 18 | GDMT in CKD and Emerging Therapies for Fluid Balance | 16:17 |
| 19 | HF with Preserved Ejection Fraction in Women | 12:44 |
| 20 | Obesity in HFpEF and Afib | 15:30 |
| 21 | Group III and IV Pulmonary Hypertension | 21:21 |
| 22 | Hypertrophic Cardiomyopathy: Mimickers and Treatment | 19:59 |
Reviews
There are no reviews yet.